Free Trial
OTCMKTS:NURPF

Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

C$8.45 0.00 (0.00%)
(As of 11/7/2024 ET)

About Neuren Pharmaceuticals Stock (OTCMKTS:NURPF)

Key Stats

Today's Range
C$8.45
C$8.45
50-Day Range
C$6.61
C$10.33
52-Week Range
C$6.61
C$17.21
Volume
N/A
Average Volume
3,219 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
1st Percentile Overall Score

NURPF MarketRank™: 

Neuren Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Neuren Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neuren Pharmaceuticals is -944.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neuren Pharmaceuticals is -944.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 2429.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neuren Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving.
  • Dividend Yield

    Neuren Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Neuren Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 2429.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neuren Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving.
  • News Sentiment

    Neuren Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Neuren Pharmaceuticals this week, compared to 0 articles on an average week.
Receive NURPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NURPF Stock News Headlines

The secret supplier behind NVIDIA, Tesla and Microsoft
The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.
Neuren Pharmaceuticals Updates Policy Amid Financial Growth
Neuren Pharmaceuticals Limited (NURPF) Gets a Buy from Wilsons
3 Undervalued Small Caps In Australia With Insider Action
PCI Biotech Holding ASA (4QG.F)
See More Headlines

NURPF Stock Analysis - Frequently Asked Questions

Neuren Pharmaceuticals' stock was trading at C$16.98 at the beginning of the year. Since then, NURPF stock has decreased by 50.2% and is now trading at C$8.45.
View the best growth stocks for 2024 here
.

Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NURPF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (OTCMKTS:NURPF) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners